Browsing Tag
Relmada Therapeutics
1 post
Relmada gains FDA support for dual Phase 3 study paths of NDV-01 in non-muscle invasive bladder cancer
Find out how Relmada secured FDA alignment on dual Phase 3 paths for NDV-01 in NMIBC, opening two routes toward approval and a potential new bladder-sparing therapy.